microRNA-181a is associated with poor prognosis of colorectal cancer

microRNA-181a is associated with poor prognosis of colorectal cancer
复制标题

DOI:
10.3892/or.2012.2059
复制
发表时间:
2012-12-01
期刊:
影响因子:
4.2
通讯作者:
Mori, Masaki
Mori, Masaki
中科院分区:
医学3区
文献类型:
--
作者:
Nishimura, Junichi;Handa, Rio;Mori, Masaki

文献摘要

被引文献

相似文献

MiRNAs通过降解mRNA和翻译抑制,在转录后水平调控基因表达。最近的研究表明miR-181a在几种类型的癌症中表达异常;然而,miR-181a在结直肠癌(CRC)中的临床意义尚不清楚。我们通过使用实时定量聚合酶链式反应(qRT-PCR)分析162例结直肠癌患者miR-181a的表达来解决这个问题。MiR-181a在正常结肠和结直肠癌组织中的表达差异无统计学意义。根据miR-181a的表达将癌组织样本分为低表达组和高表达组。两组临床病理因素及预后比较显示,高表达组预后明显差于低表达组(P=0.011)。多因素分析显示miR-181a高表达是影响结直肠癌预后的独立因素。但是,miR-181a的表达与临床病理参数无关。体外分析表明,miR-181a的过表达在mRNA水平上抑制了位于10号染色体上的抑癌基因磷酸酶和张力蛋白同源基因(PTEN)的表达。提示miR-181a可能是结直肠癌患者的一个新的独立预后因素。
miRNAs regulate gene expression at the post-transcriptional level by degradation of mRNA and translational repression. Recent studies have shown that miR-181a is dysregulated in several types of cancer; however, the clinical significance of miR-181a in colorectal cancer (CRC) remains unclear. We addressed this question by using quantitative real-time PCR (qRT-PCR) to analyze miR-181a expression in 162 CRC patients. There was no significant difference in miR-181a expression in normal colon vs. colorectal cancer tissue. The cancer tissue samples were categorized into a low and high expression group based on miR-181a expression. Comparison of the clinicopathological factors and prognosis in these two groups showed that the high expression group had a significantly poorer prognosis than the low expression group (P=0.011). Multivariate analysis indicated that high miR-181a expression was an independent significant prognostic factor for CRC. However, there no correlation was observed between miR-181a expression and clinicopathological parameters. In vitro analysis revealed that the overexpression of miR-181a repressed the expression of the tumor suppressor, phosphatase and tensin homolog (PTEN) located on chromosome 10, at the mRNA level. These data suggest that miR-181a may be a new independent prognostic factor for CRC patients.